Dr. Shau-Feng Chang is the co-founder of BELX Bio-Pharmaceutical Co. Ltd., a R&D oriented Biotechnology company that develops new botanical drugs as therapeutically agents.
Before devoting her work fulltime to BELX, Shau-Feng worked in Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI) in Taiwan. ITRI is a nonprofit and one of the world’s leading technology R&D organization engaging in applied research and technical services.
During her 20 years tenure at ITRI, Shau-Feng has accumulated excellent experiences in new drug preclinical development as well as IND application. She optimized general botanical medical benefits to effective botanical new drugs for many medical unmet needs including anti-viruses, cancer treatment and aging diseases. With innovative research, solid results, & complete IP protection, Shau-Feng established BELX in 2015 and extended her expertise in clinical trials.
The on-going phase I clinical trial using botanical new drug BEL-X-HG was approved by both US FDA and Taiwan FDA, and started in May, 2017.
Shau-Feng leads the company to collaborate with local and international partners in clinical trials, product co-development, and joint venture, becoming the leader in botanical new drugs and maximizing the value of the company.